Efficacy and Tolerability of Intramuscular and Oral Meloxicam in Patients with Acute Lumbago: A Comparison with Intramuscular and Oral Piroxicam

References

• Auvinet B, Ziller R, Appelboom T, Velicitat P. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin. Ther. 1995; 17: 1078–10901. Auvinet B, Ziller R, Appelboom T, Velicitat P. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin. Ther. 1995; 17: 1078–1090
   PubMed Web of Science ®Google Scholar
• Borenstein D. Medical therapy of low back pain. Orthop. Rev. 1993; 22: 20–252. Borenstein D. Medical therapy of low back pain. Orthop. Rev. 1993; 22: 20–25
   PubMedGoogle Scholar
• Bullinger M, Kirchberger I, von Steinbiichel N. Der Fragebogen Alltagsleben - ein Verfahren zur Erfassung der gesundheitsbezogenen Lebensqualitt. Z. Med. Psychol. 1993; 2: 121–1313. Bullinger M, Kirchberger I, von Steinbiichel N. Der Fragebogen Alltagsleben - ein Verfahren zur Erfassung der gesundheitsbezogenen Lebensqualitt. Z. Med. Psychol. 1993; 2: 121–131
   Google Scholar
• Cacace L. Elevated serum CPK after drug injections. N. Engl. J. Med. 1972; 287: 309–3104. Cacace L. Elevated serum CPK after drug injections. N. Engl. J. Med. 1972; 287: 309–310
   PubMed Web of Science ®Google Scholar
• Churchill L, Graham A G, Shih C-K., Pauletti D, Farina P R, Grob P M. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharma-cology 1996; 4: 125–1355. Churchill L, Graham A G, Shih C-K., Pauletti D, Farina P R, Grob P M. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharma-cology 1996; 4: 125–135
   Google Scholar
• Colberg K, Hettich M, Sigmund R, Degner F L. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr. Med. Res. Opin. 1996; 13: 363–3776. Colberg K, Hettich M, Sigmund R, Degner F L. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr. Med. Res. Opin. 1996; 13: 363–377
   PubMed Web of Science ®Google Scholar
• Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br. J. Rheumatol. 1996; 35(Suppl 1)68–777. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br. J. Rheumatol. 1996; 35(Suppl 1)68–77
   PubMedGoogle Scholar
• Engelhardt G, Bögel R, Schnitzler Chr, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem. Pharmacol. 1996; 51: 21–288. Engelhardt G, Bögel R, Schnitzler Chr, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem. Pharmacol. 1996; 51: 21–28
   PubMed Web of Science ®Google Scholar
• Engelhardt G, Bögel R, Schnitzler Chr, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem. Pharmacol. 1996; 51: 29–389. Engelhardt G, Bögel R, Schnitzler Chr, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem. Pharmacol. 1996; 51: 29–38
   PubMed Web of Science ®Google Scholar
• Frank A. Low back pain. Br. Med. J. 1993; 306: 901–90910. Frank A. Low back pain. Br. Med. J. 1993; 306: 901–909
   PubMed Web of Science ®Google Scholar
• Fries J F. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J. Rheumatol. 1991; 18(Suppl 28)6–1011. Fries J F. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J. Rheumatol. 1991; 18(Suppl 28)6–10
   Google Scholar
• Gabriel S E, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann. Intern. Med. 1991; 115: 787–79612. Gabriel S E, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann. Intern. Med. 1991; 115: 787–796
   PubMed Web of Science ®Google Scholar
• Ghozlan P R, Bernhardt M, Velicitat P, Bluhmki E. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br. J. Rheumatol. 1996; 35(Suppl 1)51–5513. Ghozlan P R, Bernhardt M, Velicitat P, Bluhmki E. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br. J. Rheumatol. 1996; 35(Suppl 1)51–55
   PubMedGoogle Scholar
• Helfgott S M, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity. J. Am. Med. Assoc. 1990; 264: 2660–266214. Helfgott S M, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity. J. Am. Med. Assoc. 1990; 264: 2660–2662
   PubMed Web of Science ®Google Scholar
• Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br. J. Rheumatol. 1996; 35(Suppl 1)39–4315. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br. J. Rheumatol. 1996; 35(Suppl 1)39–43
   PubMedGoogle Scholar
• Langman M JS, Well J, Wainwright P, Lawson D H, Rawlins M D, Logan R FA, Murphy M, Vessey M P, Colin-Jones D G. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–107816. Langman M JS, Well J, Wainwright P, Lawson D H, Rawlins M D, Logan R FA, Murphy M, Vessey M P, Colin-Jones D G. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–1078
   PubMed Web of Science ®Google Scholar
• Lindén B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br. J. Rheumatol. 1996; 35(Suppl 1)35–3817. Lindén B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br. J. Rheumatol. 1996; 35(Suppl 1)35–38
   PubMedGoogle Scholar
• Murray M D, Brater D C. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 1993; 32: 435–46518. Murray M D, Brater D C. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 1993; 32: 435–465
   Google Scholar
• Narjes H, Türck D, Busch U, Heinzel G, Nehmiz G. Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br. J. Clin. Pharmacol. 1996; 41: 135–13919. Narjes H, Türck D, Busch U, Heinzel G, Nehmiz G. Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br. J. Clin. Pharmacol. 1996; 41: 135–139
   PubMed Web of Science ®Google Scholar
• Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. Improved Non-steroid Anti-inflammatory Drugs - COX-2 Enzyme Inhibitors, J Vane, J Botting, R Botting. Kluwer, London 1996; 103–11920. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. Improved Non-steroid Anti-inflammatory Drugs - COX-2 Enzyme Inhibitors, J Vane, J Botting, R Botting. Kluwer, London 1996; 103–119
   Google Scholar
• Rao K V, Balakrishna N. Feasibility of Broka's index for the nutritional status of adults. Indian J. Med. Res. 1995; 102: 173–17821. Rao K V, Balakrishna N. Feasibility of Broka's index for the nutritional status of adults. Indian J. Med. Res. 1995; 102: 173–178
   PubMed Web of Science ®Google Scholar
• Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br. J. Rheurnatol. 1996; 35(Suppl 1)13–1622. Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br. J. Rheurnatol. 1996; 35(Suppl 1)13–16
   PubMedGoogle Scholar
• Uthgenannt H. Comparison of enteral loss of blood during oral administration of three non-steroidal anti-inflammatory agents: diclofenac, feprazone and indomethacin. Feprazone: New Biological and Clinical Aspects, F D Hart, 1979; 1079: 16, 9th European Congress on Rheumatology, Wiesbaden, 2–8 September. Exc. Med.23. Uthgenannt H. Comparison of enteral loss of blood during oral administration of three non-steroidal anti-inflammatory agents: diclofenac, feprazone and indomethacin. Feprazone: New Biological and Clinical Aspects, F D Hart, 1979; 1079: 16, 9th European Congress on Rheumatology, Wiesbaden, 2–8 September. Exc. Med.
   Google Scholar
• Vaccarino V, Sirtori C R, Bufalino L. Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers. Curr. Ther. Res. 1989; 45: 1–1324. Vaccarino V, Sirtori C R, Bufalino L. Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers. Curr. Ther. Res. 1989; 45: 1–13
   Web of Science ®Google Scholar
• Vane J. Towards a better aspirin. Nature 1994; 367: 215–21625. Vane J. Towards a better aspirin. Nature 1994; 367: 215–216
   PubMed Web of Science ®Google Scholar
• Vane J R, Botting R M. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 1995; 44: 1–1026. Vane J R, Botting R M. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 1995; 44: 1–10
   PubMed Web of Science ®Google Scholar
• Wojtulewski J A, Schattenkirchner M, Barceló F, Le Loët X, Bevis P JR, Bluhmki E, Distel M. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol. 1996; 35(Suppl 1)22–2827. Wojtulewski J A, Schattenkirchner M, Barceló F, Le Loët X, Bevis P JR, Bluhmki E, Distel M. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol. 1996; 35(Suppl 1)22–28
   PubMedGoogle Scholar